Pituitary Destruction by Injection of Radioactive Substance and Section of the Pituitary Stalk for Advanced Cancer

por Davies, F. L., Buxton, P. H.
Publicado 1957

Reply to letters on review ‘Evolving treatment strategies for myeloma’

por Morgan, G J, Davies, F E
Publicado 2005

Evolving treatment strategies for myeloma

por Morgan, G J, Davies, F E
Publicado 2005

Abdominal pain in adolescent females: a single-centre audit and review of management

por Gallagher, F, Jahn, H, Davies, F
Publicado 2013

STUDIES ON VITAL STAINING : V. DOUBLE STAINING WITH BRILLIANT VITAL RED AND NIAGARA SKY BLUE. CORRELATION OF HISTOLOGICAL WITH PHYSIOLOGICAL DATA

por Davies, F. B., Wadsworth, R. C., Smith, H. P.
Publicado 1930

Streptococcal superantigen‐induced expansion of human tonsil T cells leads to altered T follicular helper cell phenotype, B cell death and reduced immunoglobulin release

por Davies, F. J., Olme, C., Lynskey, N. N., Turner, C. E., Sriskandan, S.
Publicado 2019

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical applica...

por Aronson, L I, Davenport, E L, Mirabella, F, Morgan, G J, Davies, F E
Publicado 2013

‘You are just left to get on with it’: qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis

por Davies, F, Edwards, A, Brain, K, Edwards, M, Jones, R, Wallbank, R, Robertson, N P, Wood, F
Publicado 2015

Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease bur...

por Giles, S.L., deSouza, N.M., Collins, D.J., Morgan, V.A., West, S., Davies, F.E., Morgan, G.J., Messiou, C.
Publicado 2015

Improved contact tracing using network analysis and spatial-temporal proximity

por Myall, A., Peach, R., Wan, Y., Mookerjee, S., Jauneikaite, E., Bolt, F., Price, J., Davies, F., Weisse, A., Holmes, A.H., Barahona, M.
Publicado 2022

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

por Cavenagh, J, Oakervee, H, Baetiong-Caguioa, P, Davies, F, Gharibo, M, Rabin, N, Kurman, M, Novak, B, Shiraishi, N, Nakashima, D, Akinaga, S, Yong, K
Publicado 2017

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

por Pawlyn, C, Fowkes, L, Otero, S, Jones, J R, Boyd, K D, Davies, F E, Morgan, G J, Collins, D J, Sharma, B, Riddell, A, Kaiser, M F, Messiou, C
Publicado 2016

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of...

por Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B
Publicado 2016

Realist analysis of whether emergency departments with primary care services generate ‘provider-induced demand’

por McFadzean, I. J., Edwards, M., Davies, F., Cooper, A., Price, D., Carson-Stevens, A., Dale, J., Hughes, T., Porter, A., Harrington, B., Evans, B., Siriwardena, N., Anderson, P., Edwards, A.
Publicado 2022

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

por Walker, B A, Wardell, C P, Brioli, A, Boyle, E, Kaiser, M F, Begum, D B, Dahir, N B, Johnson, D C, Ross, F M, Davies, F E, Morgan, G J
Publicado 2014

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PR...

por Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T., Puig, N., Ren, K., Silar, J., Enwemadu, V., Cherepanov, D., Stull, D. M., Leleu, X.
Publicado 2022

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

por Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S
Publicado 2014

Inhibiting MEK in MAPK pathway-activated myeloma

por Heuck, C J, Jethava, Y, Khan, R, van Rhee, F, Zangari, M, Chavan, S, Robbins, K, Miller, S E, Matin, A, Mohan, M, Ali, S M, Stephens, P J, Ross, J S, Miller, V A, Davies, F, Barlogie, B, Morgan, G
Publicado 2016

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

por Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C.
Publicado 2021

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

por Papanikolaou, X, Alapat, D, Rosenthal, A, Stein, C, Epstein, J, Owens, R, Yaccoby, S, Johnson, S, Bailey, C, Heuck, C, Tian, E, Joiner, A, van Rhee, F, Khan, R, Zangari, M, Jethava, Y, Waheed, S, Davies, F, Morgan, G, Barlogie, B
Publicado 2015